LAUSANNE, Switzerland, IRVINE, CA, USA – February 22, 2006 - IsoTis
OrthoBiologics (SWX/Euronext: ISON) (TSX: ISO) today announced it has
appointed Alan Donze as Vice President Sales.

From 1991 until recently, Alan Donze was at Stryker Corporation, one of
the world’s largest orthopedic companies. From 1999 to 2004, Donze was
Vice President and General Manager of Stryker Communications where he was
instrumental in the development of the “Orthopedic Operating Room of the
Future,” using state of the art communication technology. In addition,
Donze managed Stryker’s Endoscopic Services program, which provided
specialty outsourced technicians to the orthopedic surgical marketplace.
Managed by Donze from start-up, both companies belong to Stryker’s
MedSurg Equipment division, the company’s fastest growing business.
Between 1991 and 1999, Alan held different sales and marketing positions
of increasing responsibility at Stryker Endoscopy, including Director of
Strategic Marketing, Southeast Regional Sales Manager and Endoscopy Sales
Representative. He holds a BS from Louisiana State University.

Pieter Wolters, President and CEO of IsoTis OrthoBiologics said: “We are
pleased to consistently attract top talent in the industry, and extend a
warm welcome to Alan, who will lead our global sales effort. Throughout
his career at Stryker Alan has shown leadership and entrepreneurial
spirit in driving successful sales efforts in different surgical fields.
Over the years he has built up a first rate network among surgeons and
medical professionals at leading teaching institutions, which will bring
great value to IsoTis.”

Alan replaces former IsoTis Vice President of Sales Jim Abraham, who
recently left the Company to operate a start-up opportunity in spine
technology.

Wolters continued “We wish Jim Abraham all the best in his new
endeavours. Jim was a highly valued member of our team and played an
important role in focusing our sales effort and accelerating our 2005
growth.”

IsoTis will publish its full year 2005 results on February 27 before
markets open. At 3 p.m. CET/9 a.m. ET/6a.m. PT, the Company will hold an
analyst meeting at SWX Convention Point in Zurich and a conference call
to discuss these results.

IsoTis OrthoBiologics has a product portfolio with several innovative and
proprietary natural and synthetic bone graft substitutes on the market
and others in development, an established North American independent
distribution network, and an expanding international presence. The
company’s main commercial operations are based out of Irvine, CA; its
international sales headquarters is based in Lausanne, Switzerland.

reactie XEA.nl,
Dit geeft ons een goed signaal over de gang van zaken bij Isotis.


berciht om 17.46 uur
In Zurich is ISOTIS N 22/02/06 17:30:08 Zw.f 2.1 +o.11 (5.53%) omzet 477'848